Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286110579> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W4286110579 endingPage "S51" @default.
- W4286110579 startingPage "S51" @default.
- W4286110579 abstract "Dupilumab was previously shown to reduce thymus and activation-regulated chemokine (TARC/CCL17) and total IgE levels in multiple type 2 inflammatory diseases, including atopic dermatitis (AD). Here, we assess the effects of dupilumab treatment on these biomarkers of type 2 inflammation in children aged 6 months – < 6 years with moderate-to-severe AD. In LIBERTY AD INFANT/PRE-SCHOOL (NCT03346434 part B), a phase 3, double-blind trial, children aged ≥ 6 months – < 6 years with moderate-to-severe AD inadequately controlled with topical therapies were randomized 1:1 to subcutaneous dupilumab (200 mg if baseline weight ≥ 5 – < 15 kg, 300 mg if ≥ 15 – < 30 kg) or placebo every 4 weeks for 16 weeks. All patients received standardized low-potency topical corticosteroids. Serum for biomarker analysis was collected at baseline, Week 4, and Week 16. Baseline median serum TARC and total IgE levels for dupilumab/placebo groups (n = 83/79) were 3,295/3,190 pg/mL and 2,190/3,240 kU/L, respectively. After 16 weeks of treatment, median % change from baseline in dupilumab/placebo was –83.1%/–12.8% for TARC and –71.2%/28.1% for total IgE (both P<0.0001). Similar reductions were observed in dupilumab- vs placebo-treated patients for all tested serum allergen-specific IgEs (peanut, egg white, soybean, Dermatophagoides farinae and Dermatophagoides pteronyssinus). Dupilumab significantly reduced serum TARC and total and allergen-specific IgEs in children aged 6 months – < 6 years with moderate-to-severe AD vs placebo-treated controls, reflecting reduction of systemic type 2 inflammation." @default.
- W4286110579 created "2022-07-21" @default.
- W4286110579 creator A5005051230 @default.
- W4286110579 creator A5020095047 @default.
- W4286110579 creator A5024365532 @default.
- W4286110579 creator A5032509326 @default.
- W4286110579 creator A5055081212 @default.
- W4286110579 creator A5071933191 @default.
- W4286110579 date "2022-08-01" @default.
- W4286110579 modified "2023-09-24" @default.
- W4286110579 title "297 Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis" @default.
- W4286110579 doi "https://doi.org/10.1016/j.jid.2022.05.305" @default.
- W4286110579 hasPublicationYear "2022" @default.
- W4286110579 type Work @default.
- W4286110579 citedByCount "0" @default.
- W4286110579 crossrefType "journal-article" @default.
- W4286110579 hasAuthorship W4286110579A5005051230 @default.
- W4286110579 hasAuthorship W4286110579A5020095047 @default.
- W4286110579 hasAuthorship W4286110579A5024365532 @default.
- W4286110579 hasAuthorship W4286110579A5032509326 @default.
- W4286110579 hasAuthorship W4286110579A5055081212 @default.
- W4286110579 hasAuthorship W4286110579A5071933191 @default.
- W4286110579 hasBestOaLocation W42861105791 @default.
- W4286110579 hasConcept C126322002 @default.
- W4286110579 hasConcept C141105273 @default.
- W4286110579 hasConcept C142724271 @default.
- W4286110579 hasConcept C159654299 @default.
- W4286110579 hasConcept C185592680 @default.
- W4286110579 hasConcept C203014093 @default.
- W4286110579 hasConcept C204787440 @default.
- W4286110579 hasConcept C207480886 @default.
- W4286110579 hasConcept C27081682 @default.
- W4286110579 hasConcept C2776173921 @default.
- W4286110579 hasConcept C2777697326 @default.
- W4286110579 hasConcept C2778329239 @default.
- W4286110579 hasConcept C2779824493 @default.
- W4286110579 hasConcept C2780501606 @default.
- W4286110579 hasConcept C2780564577 @default.
- W4286110579 hasConcept C2780699399 @default.
- W4286110579 hasConcept C2781197716 @default.
- W4286110579 hasConcept C55493867 @default.
- W4286110579 hasConcept C71924100 @default.
- W4286110579 hasConcept C90924648 @default.
- W4286110579 hasConceptScore W4286110579C126322002 @default.
- W4286110579 hasConceptScore W4286110579C141105273 @default.
- W4286110579 hasConceptScore W4286110579C142724271 @default.
- W4286110579 hasConceptScore W4286110579C159654299 @default.
- W4286110579 hasConceptScore W4286110579C185592680 @default.
- W4286110579 hasConceptScore W4286110579C203014093 @default.
- W4286110579 hasConceptScore W4286110579C204787440 @default.
- W4286110579 hasConceptScore W4286110579C207480886 @default.
- W4286110579 hasConceptScore W4286110579C27081682 @default.
- W4286110579 hasConceptScore W4286110579C2776173921 @default.
- W4286110579 hasConceptScore W4286110579C2777697326 @default.
- W4286110579 hasConceptScore W4286110579C2778329239 @default.
- W4286110579 hasConceptScore W4286110579C2779824493 @default.
- W4286110579 hasConceptScore W4286110579C2780501606 @default.
- W4286110579 hasConceptScore W4286110579C2780564577 @default.
- W4286110579 hasConceptScore W4286110579C2780699399 @default.
- W4286110579 hasConceptScore W4286110579C2781197716 @default.
- W4286110579 hasConceptScore W4286110579C55493867 @default.
- W4286110579 hasConceptScore W4286110579C71924100 @default.
- W4286110579 hasConceptScore W4286110579C90924648 @default.
- W4286110579 hasIssue "8" @default.
- W4286110579 hasLocation W42861105791 @default.
- W4286110579 hasOpenAccess W4286110579 @default.
- W4286110579 hasPrimaryLocation W42861105791 @default.
- W4286110579 hasRelatedWork W2114860319 @default.
- W4286110579 hasRelatedWork W2748617188 @default.
- W4286110579 hasRelatedWork W3089207533 @default.
- W4286110579 hasRelatedWork W3129156840 @default.
- W4286110579 hasRelatedWork W4221014321 @default.
- W4286110579 hasRelatedWork W4292511020 @default.
- W4286110579 hasRelatedWork W4306875639 @default.
- W4286110579 hasRelatedWork W4308695704 @default.
- W4286110579 hasRelatedWork W4324065251 @default.
- W4286110579 hasRelatedWork W4366171240 @default.
- W4286110579 hasVolume "142" @default.
- W4286110579 isParatext "false" @default.
- W4286110579 isRetracted "false" @default.
- W4286110579 workType "article" @default.